arrow
Y

Yuki Obayashi

Graduate School of Medicine
H指数:13
被引数:891

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Midterm outcomes after TAVR or SAVR in low-risk patients with severe aortic stenosis in the real clinical practice in Japan

日本真实临床实践中,低危重度主动脉瓣狭窄患者经导管主动脉瓣置换术或外科主动脉瓣置换术的中期结局

2026-08-120
PRE
Cardiac damage stages at follow-up and subsequent clinical outcomes in patients with severe aortic stenosis

随访期间严重主动脉瓣狭窄患者的心脏损伤阶段及后续临床结局

2026-05-260
PRE
Aspirin versus clopidogrel beyond 1 month after percutaneous coronary intervention in high bleeding risk patients with or without acute coronary syndrome: a subgroup analysis from the STOPDAPT-3 trial

阿司匹林与氯吡格雷在经皮冠状动脉介入治疗1个月后高出血风险患者(无论是否伴有急性冠状动脉综合征)中的比较:STOPDAPT-3试验的亚组分析

2026-04-040
PRE
Effect of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention With Aspirin-Free Strategy

无阿司匹林策略下质子泵抑制剂对经皮冠状动脉介入治疗患者的影响

2026-02-011
OAAI
Cardiac Damage Stages and Clinical Outcomes in Patients With Severe Aortic Stenosis
2026-01-011
OAAI
Low-flow and normal-flow low-gradient aortic stenosis with reduced left ventricular ejection fraction. Insights from the CURRENT AS Registry-2

低血流和正常血流低梯度主动脉瓣狭窄伴左心室射血分数降低。CURRENT AS Registry-2注册研究的启示

2025-12-170
PRE
Aspirin vs Clopidogrel 1 Month After Acute Coronary Syndrome With High-Bleeding Risk or ST-Segment Elevation

急性冠状动脉综合征伴高出血风险或ST段抬高1个月后阿司匹林与氯吡格雷的比较

2025-06-040
PRE
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial
2025-01-250
OAAI
Availability of transcatheter aortic valve implantation across hospitals and differences in strategies and clinical outcomes in patients with severe aortic stenosis

跨医院经导管主动脉瓣植入的可用性以及严重主动脉瓣狭窄患者的策略和临床结局的差异

2024-11-280
PRE
Concomitant Mitral Regurgitation in Severe Aortic Stenosis - Insights From the CURRENT AS Registry-2-

严重主动脉瓣狭窄伴二尖瓣反流-来自当前AS注册的见解-2-

2024-11-250
OA
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial
2024-10-231
PRE
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial
2024-08-311
OA
Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 Trial
2024-08-060
OAAI
An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention

复杂经皮冠状动脉介入治疗后立即治疗的无阿司匹林策略

2024-05-013
PRE
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial
2024-02-2048
PRE
Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial

基于急性冠状动脉综合征亚型和高出血风险的无阿司匹林经皮冠状动脉介入治疗的STOPDAPT-3试验

2024-01-295
PRE
In-hospital outcomes after SAVR or TAVI in patients with severe aortic stenosis
2023-06-224
OAAI
Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome-A Post Hoc Secondary Analysis of STOPDAPT-2 ACS
2023-04-256
OA
Tricuspid regurgitation in elderly patients with acute heart failure: insights from the KCHF registry
2023-03-294
OAAI